News

UroToday2d
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...
UroToday1d
Bayer to Unveil Latest NUBEQA® (darolutamide) Data and Prostate Cancer Research at American Urological Association (AUA) 2025 Annual Meeting
• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...
UroToday2d
When Should We Use 18F-FDG PET? "Presentation" - Andrei Iagaru
When Should We Use 18F-FDG PET? "Presentation" - Andrei Iagaru ...
UroToday2d
Lutetium PSMA Beyond Six Cycles Extended Treatment and Re-Challenge Approaches "Presentation" - Matthias Eiber
Lutetium PSMA Beyond Six Cycles Extended Treatment and Re-Challenge Approaches "Presentation" - Matthias Eiber ...
UroToday2d
Do differences in secondary treatment explain mortality impact of prostate cancer screening? - A randomized screening trial.
The European Randomized study of screening for prostate cancer (ERSPC) demonstrated a reduction in prostate cancer (PC) mortality via PSA-based screening. We evaluated whether treatments for ...
UroToday2d
Post-Treatment SPECT Imaging for Personalized Radiopharmaceutical Therapy "Presentation" - Carlos Uribe
Post-Treatment SPECT Imaging for Personalized Radiopharmaceutical Therapy "Presentation" - Carlos Uribe ...
UroToday2d
Predictors of bladder spasm during catheter-indwelling in discharged patients after robot-assisted laparoscopic radical prostatectomy.
Postoperative bladder spasm is a prevalent complication during the indwelling catheter period after radical prostatectomy (RP), affecting patient recovery and quality of life. This study aimed to ...
UroToday2d
Identification of a 5-Gene Signature Panel for the Prediction of Prostate Cancer Progression - Beyond the Abstract
Despite this favorable survival estimate for localized diseases, prostate cancer is still predicted to contribute to 35,250 new cancer deaths in 2024. 1 This accounts for 5.8% of all cancer-driven ...
UroToday2d
Prognostic impact of combined loss of RB1, p53 and p21 in muscle-invasive bladder cancer.
Muscle-invasive bladder cancer (MIBC) represents a genetically heterogeneous disease with limited prognostic markers. This study aimed to validate the prognostic relevance of combined alterations in ...